By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TG Therapeutics, Inc. 

787 Seventh Avenue
48th Floor
New York  New York  10019  U.S.A.
Phone: 212-554-4484 Fax: 212-554-4531


SEARCH JOBS


Industry
Pharmaceutical






Company News
TG Therapeutics, Inc. (MHA) Enters Into A Global Collaboration With Checkpoint Therapeutics To Develop And Commercialize Novel Immuno-Oncology Targeted Antibodies 3/4/2015 7:12:48 AM
TG Therapeutics, Inc. (MHA) To Present At The Cowen and Company 35th Annual Health Care Conference 3/2/2015 7:49:02 AM
TG Therapeutics, Inc. (MHA) To Present At The 17th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference 2/4/2015 7:52:50 AM
TG Therapeutics, Inc. (MHA) To Provide An Update On Its Clinical Programs And Corporate Goals For 2015 At The 33rd Annual J.P. Morgan Healthcare Conference 1/15/2015 7:11:52 AM
TG Therapeutics, Inc. (MHA) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/8/2015 12:29:22 PM
TG Therapeutics, Inc. (MHA) Announces Appointment Of Kenneth Hoberman To Board Of Directors 12/17/2014 7:45:45 AM
TG Therapeutics, Inc. (MHA) Release: Preliminary Data From Ongoing Phase I/II Dose Escalation Study Of TG-1101 (Ublituximab) In Combination With TGR-1202 In Heavily Pre-Treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity And Safety 12/9/2014 10:49:31 AM
TG Therapeutics, Inc. (MHA) Release: Data From Phase 2 Clinical Trial Of TG-1101 (Ublituximab) And Ibrutinib Shows Compelling Clinical Activity In Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) 12/9/2014 10:37:35 AM
TG Therapeutics, Inc. (MHA) Release: Interim Data From Phase 1 Dose Escalation Clinical Trial Of TGR-1202, The Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity And Lack Of Hepatic Toxicity In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma 12/8/2014 7:24:52 AM
TG Therapeutics, Inc. (MHA) Announces Collaboration For A Clinical Trial Of TGR-1202 In Combination With Ibrutinib (Imbruvica) For Patients With Select B-Cell Malignancies 12/1/2014 10:32:34 AM
12345678910...
//-->